Subsequent treatment of control arm of adjuvant trials is causing controversy due to subsequent IO access. In the +ve renal & bladder studies 81%/48% and ~62%/~36% received further therapy/IO respectively.However the figure below shows these analysis are time dependant & complex

Hear from Drs. Sumanta K. Pal, MD, FASCO, Pedro C Barata, MD MSc FACP, McDermott, & Tian Zhang, MD, MHS how to use team-based strategies for mitigating & managing adverse events to allow your patients with #RCC to continue to receive optimal care! Developed with PeerView: bit.ly/4coeVh0  #GU24 #MedEd

At #JSMO with 3 controversies from ASCOGU 1) The -ve OS adjuvant pembro data in UC questions this approach more broadly. Censoring ++ on KM curve though. 2) More data needed to prove atezo is active with cabo in CRPC. 3)Ipi/nivo looks as good as anything else in good risk M1 RCC

Wow. Update from Dr. Tannir MD Anderson Cancer Center presenting 8 year f/u for CM214. For patients who responded to nivo+ipi, half are still responding 8 years later. Also interesting OS for IMDC favorable risk. OncLive.com OncoAlert UroToday.com KidneyCAN Kidney Cancer

#RaquibHannan UTSW Radiation Oncology UTSW Simmons Cancer Center showcases the ECOG-ACRIN Cancer Research Group #SOAR trial — open now and available for all NCI CTEP Clinical Research sites! #GU24 OncoAlert

Learn from Drs. Sumanta K. Pal, MD, FASCO, Pedro C Barata, MD MSc FACP, McDermott, & Tian Zhang, MD, MHS how to use team-based strategies for mitigating & managing adverse events to allow your patients with #RCC to continue to receive optimal care! 1/25 at 6:00 PM PST. With @KCCure! bit.ly/RCC24T #GU24

Tian Zhang, MD, MHS PeerView Sumanta K. Pal, MD, FASCO Pedro C Barata, MD MSc FACP Uromigos OncoAlert KCCure Dream team!!

Ms Sally Dale with a touching story on her #kidneycancer journey and her perspective w her oncologist Yousef Zakharia looking on — immunotherapy has been “very good”. A journey which is not easy but which is accepted. Kidney Cancer KCCure

Tian Zhang, MD, MHS Phillip Pierorazio Kidney Cancer KCCure Gretchen Vaughan Laurence Albiges Payal Kapur Dan George Hans Hammers Dena Battle Stephanie Berg Alexander Kutikov MD Congratulations & thank you Tian Zhang, MD, MHS Phillip Pierorazio for leading a phenomenally inspiring meeting, bringing together our Kidney Cancer community to learn, collaborate, celebrate & honor our patients and innovators & brainstorm next steps! Kidney Cancer KCCure #IKCSNA23

Excellent discussion of Roberto Iacovelli TIDE-A from by friend Deborah Mukherji - our KCCure patients want to be able to stop therapy once effective, but would feel more confident if we had #biomarkers #ESMO23

Remarkable moment for Bladder Cancer patients. Kudos to ⁦Tom Powles⁩ for recognizing the many patients who participated in previous negative trials. Their contribution matters and helped bring us to where we are today.

Thank you Deborah Mukherji! Wonderful #ESMO23 presentation evaluating results based on outcomes that are meaningful to #kidneycancer pts!

Thank you kindly, Elizabeth Plimack MD & @myesmo GU committee! Much more to learn about underpinnings of toxicity w/emergence of Tx w/novel MOAs & combos across GU cancers! #ESMO23 🙏🏼 to my UNITE co-captains, Vadim Koshkin MD & Tanya Jindal, & all UNITE sites for your contributions & support!

Merck's decision to use everolimus as a comparator arm was disappointing. You can race a sloth against a snail, but it doesn't prove the sloth is fast. Weak controls not only devalue results, worse - they subject trial participants to weak treatment options.

Martin Voss with very clear phase 1/2 trial of MEDI5752 bispecific CTLA4/PD1 volrustomig — excellent activity in tx naive met #kidneycancer ! ESMO - Eur. Oncology #ESMO23 OncoAlert

@kccure patient centered data on display at #ESMO23 . Huge thanks to Lisa Pickering 💉💙 for opening with this reminder. #kidneycancer patients want curative treatments!

Excellent remind by Dr. Lisa Pickering 💉💙 about what is most important for patients to achieve with new treatments for advanced RCC by KCCure . Most important is cure, then quality of life and duration of response. #ESMO23

Excited to see Dena Battle from IKCC affiliate KCCure on the agenda! Her presentation will be on patients as partners – unlocking patient advocacy to improve clinical practice and patient care.

KCCure World Bladder Cancer Patient Coalition

HUGE NEWS: EV/Pembro combo tops platinum-based chemo, a SOC for 30+years, in 1L bladder cancer: a new era ….PFS/OS met!

prnewswire.com/news-releases/…

Petros Grivas Cancers MDPI Chijioke Nze MD, MPH RMC Alliance Dr. Bishoy M. Faltas Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Kidney Cancer KCCure KidneyCAN Aung Naing jc OncoAlert MD Anderson Cancer Center Ashish M. Kamat, MD, MBBS Omar Alhalabi, MD Thank you my friend. Even negative trials like this one helped us prevent many patients from receiving ineffective therapies and get us one step closer towards eradicating #RenalMedullaryCarcinoma . #endRMC